Psychedelic Medicine Maturity in 2026: Phase 3 Positive Signal, Major M&A, and a Care-Delivery Bottleneck

Psychedelic-assisted therapies reached new clinical-translation milestones in 2025-2026: a Phase 3 positive readout for psilocybin in treatment-resistant depression, a major acquisition, and a defining FDA Complete Response Letter that clarifies the evidence and care-delivery fra

Type

evidence-claim

Domain

h10_altered_intercellular_communication

Grade

B

License

CC BY-NC 4.0

card_id

L-018

hallmarks

h10_altered_intercellular_communication

cluster

clinical_translation

primary_disease_area

depression_resistant,longevity_general

evidence_tier

B

evidence_anchor_count

5

intake_round

R23

intake_date

2026-05-26

related_experts

related_biomarkers

related_interventions

related_trials

NCT05711940

collection_pages

/research/interventions/psychedelic-assisted-therapy,/research/capital-industry/2026-translation

LongProof Longevity Dynamic · LIGHT HOPE / x1000.ai · longevity.x1000.ai · 2026 · source

Read-only aggregated view. Longevity Evidence is the source of record; this catalog shows provenance as-is — no ratings, no reviews.